ERBB2 and breast carcinoma: Systemic therapies for breast cancer, including anti-estrogen therapies, anti-Her2 therapies, and chemotherapy, are selected based upon tumor subtype (i.e., estrogen receptor and Her2 status), tumor stage, lymph node status, and other biological features relevant to risk stratification.